We are analyzing https://link.springer.com/article/10.1007/s11684-016-0488-1.

Title:
Mechanisms of resistance to third-generation EGFR tyrosine kinase inhibitors | Frontiers of Medicine
Description:
The tyrosine kinase inhibitors (TKI) of the epidermal growth factor receptor (EGFR) are becoming the first line of therapy for advanced non-small cell lung cancer (NSCLC). Acquired mutations in EGFR account for one of the major mechanisms of resistance to the TKIs. Three generations of EGFR TKIs have been used in clinical applications. AZD9291 (osimertinib; Tagrisso) is the first and only FDA approved third-generation EGFR TKI for T790M-positive advanced NSCLC patients. However, resistance to AZD9291 arises after 9–13 months of therapy. The mechanisms of resistance to third-generation inhibitors reported to date include the EGFR C797S mutation, EGFR L718Q mutation, and amplifications of HER-2, MET, or ERBB2. To overcome the acquired resistance to AZD9291, EAI045 was discovered and recently reported to be an allosteric EGFR inhibitor that overcomes T790M- and C797S-mediated resistance. This review summarizes recent investigations on the mechanisms of resistance to the EGFR TKIs, as well as the latest development of EAI045 as a fourth-generation EGFR inhibitor.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Science
Education
Health & Fitness

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We see no obvious way the site makes money.

Not every website is profit-driven; some are created to spread information or serve as an online presence. Websites can be made for many reasons. This could be one of them. Link.springer.com might be plotting its profit, but the way they're doing it isn't detectable yet.

Keywords {🔍}

pubmed, article, google, scholar, cancer, egfr, cas, lung, central, oncol, resistance, inhibitors, cell, hematol, liu, mutation, wang, nonsmall, advanced, thirdgeneration, inhibitor, lee, kim, kinase, zhang, acquired, azd, phase, res, chen, nonsmallcell, med, mechanisms, tyrosine, patients, versus, treatment, song, receptor, nsclc, zhou, park, yang, access, privacy, cookies, content, epidermal, growth, factor,

Topics {✒️}

month download article/chapter mirna-based therapeutic intervention nonsmall-cell lung cancer small-cell lung cancer structure-based design approach egfr-mutant lung cancer fourth-generation egfr inhibitor targeting drug resistance related subjects selumetinib-enhanced radioiodine uptake mutant-selective covalent inhibitor mutant-selective allosteric inhibitors xpo1/crm1-selective inhibitors overcomes t790m-mediated resistance tyrosine kinase inhibitors phase 3 trials phase iii study egfr mutation-positive advanced advanced egfr mutation-positive full article pdf monitor egfr-tki treatment phase iii affiliated cancer hospital allosteric egfr inhibitor randomised controlled trial privacy choices/manage cookies generation egfr inhibitors advanced squamous-cell egfr mutation-positive egfr-mutation- positive egfr mutation positive egfr mutation status selective bcl-2 inhibitor egfr c797s mutation afatinib versus erlotinib irreversible egfr tki c797s-mediated resistance generation alk inhibitors egfr-mutated nsclc article frontiers lung cancer patients tumor egfr status generation egfr tki egfr l718q mutation generation inhibitors reported erlotinib versus chemotherapy c797s mutation acquired acquired c797s mutation article wang advanced thyroid cancer

Questions {❓}

Can EGFR mutations in plasma or serum be predictive markers of non-small-cell lung cancer?
Nivolumab as first line monotherapy for advanced non-small cell lung cancer: could we replace first line chemotherapy with immunotherapy?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Mechanisms of resistance to third-generation EGFR tyrosine kinase inhibitors
         description:The tyrosine kinase inhibitors (TKI) of the epidermal growth factor receptor (EGFR) are becoming the first line of therapy for advanced non-small cell lung cancer (NSCLC). Acquired mutations in EGFR account for one of the major mechanisms of resistance to the TKIs. Three generations of EGFR TKIs have been used in clinical applications. AZD9291 (osimertinib; Tagrisso) is the first and only FDA approved third-generation EGFR TKI for T790M-positive advanced NSCLC patients. However, resistance to AZD9291 arises after 9–13 months of therapy. The mechanisms of resistance to third-generation inhibitors reported to date include the EGFR C797S mutation, EGFR L718Q mutation, and amplifications of HER-2, MET, or ERBB2. To overcome the acquired resistance to AZD9291, EAI045 was discovered and recently reported to be an allosteric EGFR inhibitor that overcomes T790M- and C797S-mediated resistance. This review summarizes recent investigations on the mechanisms of resistance to the EGFR TKIs, as well as the latest development of EAI045 as a fourth-generation EGFR inhibitor.
         datePublished:2016-12-23T00:00:00Z
         dateModified:2016-12-23T00:00:00Z
         pageStart:383
         pageEnd:388
         sameAs:https://doi.org/10.1007/s11684-016-0488-1
         keywords:
            EGFR
            tyrosine kinase inhibitor
            AZD9291
            EAI045
            Medicine/Public Health
            general
         image:
         isPartOf:
            name:Frontiers of Medicine
            issn:
               2095-0225
               2095-0217
            volumeNumber:10
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Higher Education Press
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Shuhang Wang
               affiliation:
                     name:Peking University Cancer Hospital
                     address:
                        name:The Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital, Beijing, China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Yongping Song
               affiliation:
                     name:Henan Cancer Hospital and the Affiliated Cancer Hospital of Zhengzhou University
                     address:
                        name:Henan Cancer Hospital and the Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Feifei Yan
               affiliation:
                     name:Peking University Cancer Hospital
                     address:
                        name:The Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital, Beijing, China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Delong Liu
               affiliation:
                     name:Henan Cancer Hospital and the Affiliated Cancer Hospital of Zhengzhou University
                     address:
                        name:Henan Cancer Hospital and the Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Mechanisms of resistance to third-generation EGFR tyrosine kinase inhibitors
      description:The tyrosine kinase inhibitors (TKI) of the epidermal growth factor receptor (EGFR) are becoming the first line of therapy for advanced non-small cell lung cancer (NSCLC). Acquired mutations in EGFR account for one of the major mechanisms of resistance to the TKIs. Three generations of EGFR TKIs have been used in clinical applications. AZD9291 (osimertinib; Tagrisso) is the first and only FDA approved third-generation EGFR TKI for T790M-positive advanced NSCLC patients. However, resistance to AZD9291 arises after 9–13 months of therapy. The mechanisms of resistance to third-generation inhibitors reported to date include the EGFR C797S mutation, EGFR L718Q mutation, and amplifications of HER-2, MET, or ERBB2. To overcome the acquired resistance to AZD9291, EAI045 was discovered and recently reported to be an allosteric EGFR inhibitor that overcomes T790M- and C797S-mediated resistance. This review summarizes recent investigations on the mechanisms of resistance to the EGFR TKIs, as well as the latest development of EAI045 as a fourth-generation EGFR inhibitor.
      datePublished:2016-12-23T00:00:00Z
      dateModified:2016-12-23T00:00:00Z
      pageStart:383
      pageEnd:388
      sameAs:https://doi.org/10.1007/s11684-016-0488-1
      keywords:
         EGFR
         tyrosine kinase inhibitor
         AZD9291
         EAI045
         Medicine/Public Health
         general
      image:
      isPartOf:
         name:Frontiers of Medicine
         issn:
            2095-0225
            2095-0217
         volumeNumber:10
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Higher Education Press
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Shuhang Wang
            affiliation:
                  name:Peking University Cancer Hospital
                  address:
                     name:The Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital, Beijing, China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Yongping Song
            affiliation:
                  name:Henan Cancer Hospital and the Affiliated Cancer Hospital of Zhengzhou University
                  address:
                     name:Henan Cancer Hospital and the Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Feifei Yan
            affiliation:
                  name:Peking University Cancer Hospital
                  address:
                     name:The Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital, Beijing, China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Delong Liu
            affiliation:
                  name:Henan Cancer Hospital and the Affiliated Cancer Hospital of Zhengzhou University
                  address:
                     name:Henan Cancer Hospital and the Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Frontiers of Medicine
      issn:
         2095-0225
         2095-0217
      volumeNumber:10
Organization:
      name:Higher Education Press
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Peking University Cancer Hospital
      address:
         name:The Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital, Beijing, China
         type:PostalAddress
      name:Henan Cancer Hospital and the Affiliated Cancer Hospital of Zhengzhou University
      address:
         name:Henan Cancer Hospital and the Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China
         type:PostalAddress
      name:Peking University Cancer Hospital
      address:
         name:The Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital, Beijing, China
         type:PostalAddress
      name:Henan Cancer Hospital and the Affiliated Cancer Hospital of Zhengzhou University
      address:
         name:Henan Cancer Hospital and the Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Shuhang Wang
      affiliation:
            name:Peking University Cancer Hospital
            address:
               name:The Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital, Beijing, China
               type:PostalAddress
            type:Organization
      name:Yongping Song
      affiliation:
            name:Henan Cancer Hospital and the Affiliated Cancer Hospital of Zhengzhou University
            address:
               name:Henan Cancer Hospital and the Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China
               type:PostalAddress
            type:Organization
      name:Feifei Yan
      affiliation:
            name:Peking University Cancer Hospital
            address:
               name:The Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital, Beijing, China
               type:PostalAddress
            type:Organization
      name:Delong Liu
      affiliation:
            name:Henan Cancer Hospital and the Affiliated Cancer Hospital of Zhengzhou University
            address:
               name:Henan Cancer Hospital and the Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:The Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital, Beijing, China
      name:Henan Cancer Hospital and the Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China
      name:The Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital, Beijing, China
      name:Henan Cancer Hospital and the Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(218)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

4.79s.

LINK . SPRINGER . COM {}